miércoles, 18 de noviembre de 2026
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer New therapy offers a meaningful treatment option for families facing a rare and serious childhood disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer?utm_medium=email&utm_source=govdelivery
The FDA has approved Lembaz (adrabetadex), the first treatment shown to reduce the risk of death in patients with infantile onset Niemann-Pick disease type C (NPC), a rare inherited disease that causes progressive neurological decline.
Lembaz is approved for patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile onset. It is given as an injection into the spinal canal every two weeks. Patients treated with Lembaz had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death. The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group.
The most common side effects include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss, and patients should have a comprehensive hearing evaluation before starting Lembaz and regularly throughout treatment.
Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario